Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
EG1
AOB8067
CAS: 693241-54-2
Chemical Name: 2-[[4-[(2-Methoxybenzoyl)amino]benzoyl]amino]-benzoic acid
100 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $31.45 | Total: $157.25 |
| 1 | 10 | $26.64 | Total: $266.40 |
| 1 | 25 | $22.57 | Total: $564.25 |
| 1 | 50 | $19.24 | Total: $962.00 |
| 1 | 100 | $16.65 | Total: $1,665.00 |
Overview
Novel specific inhibitor of Pax2 transcription activation, targeting the DNA binding domain and inhibiting embryonic kidney development
Chemical Properties
| Molecular Formula | C22H18N2O5 |
| Molecular Weight | 390.40 |
| CAS Numbers | 693241-54-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | 2-[[4-[(2-Methoxybenzoyl)amino]benzoyl]amino]-benzoic acid |
| InChl Key | GYZZRJRJYVMXNS-UHFFFAOYSA-N |
| InChl Code | InChI=1S/C22H18N2O5/c1-29-19-9-5-3-7-17(19)21(26)23-15-12-10-14(11-13-15)20(25)24-18-8-4-2-6-16(18)22(27)28/h2-13H,1H3,(H,23,26)(H,24,25)(H,27,28) |
| SMILES Code | O=C(O)C1=CC=CC=C1NC(C2=CC=C(NC(C3=CC=CC=C3OC)=O)C=C2)=O |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
EG-1; EG 1
References
1) Smith CB, et al., Using the New ASCO Clinical Practice Guideline for Palliative Care Concurrent With Oncology Care Using the TEAM Approach. Am Soc Clin Oncol Educ Book. 2017;37:714-723. doi: 10.14694/EDBK_175474. PubMed PMID: 28561696.
2) Masuda K, et al.' Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352-z. [Epub ahead of print] PubMed PMID: 28555325.